Aim: The marked increase in prevalence of obesity has been associated with an increase in obese patients seeking surgical treatment for refractory gastroesophageal reflux disease (GORD). The management of GORD in such patients remains contentious with no published guidelines.
INTRODUCTION
Gastroesophageal reflux disease (GORD) is defined as a group of symptoms and/or mucosal injury that occurs as a result of reflux of gastric contents into the oesophagus [1] . It is a frequently encountered and costly medical condition with an estimated annual cost of proton pump inhibitor use of nearly £500 million in England alone. The prevalence of GORD and obesity [body mass index (BMI) >30 kg/m 2 ] has increased significantly over the past three decades in the USA and Europe [2] [3] [4] [5] [6] . GORD is widely prevalent in obese patients; with increasing BMI considered a risk factor for developing the disease [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The marked increase in prevalence of obesity has been associated with an increase in obese patients seeking surgical treatment for refractory GORD [17] . The management of GORD in obese patients remains contentious with no consensus or published guidelines. Data are conflicting regarding the long-term efficacy of fundoplication in obese individuals compared with normal weight counterparts [18] [19] [20] [21] [22] . Nevertheless, most surgeons would agree that treatment of GORD in obese and non-obese patients requires different strategies [23] . The aim of this study was to elicit professional opinions of upper gastrointestinal (GI) surgeons towards the management of refractory GORD in obese patients.
METHODS
A snapshot 9-item online survey was undertaken between October and November 2015. Members of two UK specialist associations [Association of Upper GI Surgeons (AUGIS) and British Obesity and Metabolic Surgery Society (BOMSS)] were contacted via email and invited to participate in the survey [Supplementary Figure 1] . The questions were designed to characterize training and practice characteristics, experience, and subspecialty interest of respondents. Professional opinions were sought, regarding the optimal treatment for obese patients of varying BMI with medically refractory GORD and reasons for treatment choices.
RESULTS
A total of 451 specialist association members were emailed the link to the survey questions. All respondents were upper GI surgeons, of whom 51% were also bariatric surgeons. There was an even distribution of duration of practice as consultant surgeon amongst respondents (33% < 5 years, 27% had 5-10 years, 33% had 11-20 years, and 7% had > 20 years experience as consultant). Eighty-two percent regularly performed ≥ 10 laparoscopic and/or anti-reflux procedures per year and 51% admitted to regularly performing ≥ 10 bariatric procedures per year.
Sixty-one surgeons (79%) considered laparoscopic fundoplication the preferred option for management of refractory GORD in patients with BMI 30-34.9 kg/m 2 [ Figure 1A ]. However, only 21% and 11% would consider laparoscopic fundoplication as their preferred option for BMI 35-39.9 and ≥ 40 kg/m 2 , respectively [ Figure 1A ]. Twenty-one surgeons (20%) considered anti-reflux surgery not a preferred option for refractory GORD in obese patients. Fifty-eight percent and 80% would discuss bariatric surgery as an alternative treatment option for refractory GORD in BMI 35-39.9 and ≥ 40 kg/m 2 , respectively [ Figure 1B ]. Moreover, 74% and 58% of respondents considered a bariatric procedure the preferred option in patients, respectively, with BMI ≥ 40 kg/m 2 with refractory GORD, or BMI ≥ 35 kg/m 2 with significant comorbidities together with refractory GORD [ Figure 1C ]. Eighty percent of surgeons agreed laparoscopic Roux en-Y gastric bypass (LRYGB) was the bariatric procedure of choice for the management of obese patients with documented GORD [ Figure 1D ]. Reasons for bariatric surgery not being offered included lack of level one evidence (15%), lack of national consensus (26%), difficulty in referring patients for bariatric surgery (12%) or patient attitudes towards bariatric surgery (16%).
DISCUSSION
This snapshot survey sought to elicit UK upper GI surgeon attitudes towards the management of refractory GORD in obese patients. It demonstrated that upper GI surgeons still preferred fundoplication in patients with BMI 30-35 kg/m 2 . However, they were less likely to offer fundoplication to patients at higher BMI. The majority of surgeons would consider a bariatric procedure the preferred option for management of refractory GORD in the morbidly obese and would discuss this as an option with their patients. The majority of respondents felt that LRYGB was the best option to treat medically refractory GORD in this patient group.
Anti-reflux surgery is recognised as the treatment option of choice for medically refractory GORD [24] [25] [26] . However, patient selection is essential to achieving a good outcome [27] . To date, few studies have examined the long-term efficacy and durability of traditional anti-reflux procedures such as Nissen fundoplication in the setting of severe obesity, and results have been conflicting [18] [19] [20] [21] [22] . It has been suggested that laparoscopic anti-reflux surgery is associated with a higher failure rate in obese patients because of intraoperative technical difficulties as well as increased intra-abdominal pressure postoperatively [28] . Nevertheless, others have reported equivalent outcomes in obese and normal weight individuals [17] . Obesity and GORD have a well-defined association due to several anatomic and hormonal pathophysiologic mechanisms [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Ultimately, while the medical and surgical treatment of GORD is advancing, there is a relative lack of specific studies examining novel GORD treatments in obese patients.
Existing data demonstrate LRYGB to be associated with significant improvement in GORD symptoms [26, 27, 29] . Many morbidly obese patients with GORD also suffer additional obesity-related conditions that are improved by LRYGB. For these reasons, most experts consider LRYGB a better treatment modality than traditional anti-reflux surgery in managing GORD as it also treats underlying obesity and associated comorbidities [26, 27, 29] . The benefits of LRYGB in BMI < 30 kg/m 2 patients is less clear and needs further study [26, 27, 29] . In this survey, the attitudes of UK surgeons was consistent with previous published international studies [27] . In a similar online survey by Pagé et al. [27] who examined the opinions of Members of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) regarding the management of GORD in the setting of obesity, most surgeons would offer laparoscopic anti-reflux surgery for patients with BMI < 35 kg/m 2 and symptomatic GORD, while LRYGB was considered the procedure of choice for those patients with BMI > 35kg/m 2 [27] . However, Pagé et al. [27] suggest that morbidly obese patients with GORD, who would otherwise be best served with LRYGB, actually underwent Nissen fundoplication or no procedure at all due to financial limitations and policy exclusions. In contrast, UK surgeons would not consider bariatric surgery as their choice mainly due to the lack of national consensus and guidelines. Restrictions in commissioning in the UK may also have an impact if a significant number of patients were to undergo bariatric surgery primarily to manage reflux. The results of this survey may help inform surgeon practices pending development of much needed national consensus guidelines.
Limitations of this study include an 18% response rate, and that the opinions of specialty associations may not be representative of the wider UK surgical community. Finally, this study was designed to elicit surgeon opinions and attitudes and was not a randomised study comparing the two approaches.
In conclusion, this survey demonstrated bariatric surgery, specifically LRYGB, to be considered the preferred treatment option for BMI ≥ 35 kg/m 2 patients with refractory GORD. There is a need for published national guidance to inform clinical practice on the management of GORD in patients with severe and complex obesity.
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